Evolution of the Average Target: Outlook Therapeutics, Inc.

Evolution of the Target Price: Outlook Therapeutics, Inc.

Changes in Analyst Recommendations: Outlook Therapeutics, Inc.

d6d8e4eba58195b7cc3b25.lezy3vaQJF8ufr5Qpbp5QE56-sQmCxHYK4a6_EQAQe4.raPEv6fBfjFZSso_9-8RFz0CkZtfXSboebbzuhdEd4nF2ojnxt9OKn5Oig~b528f4f773e8a566ea692506496c21f7
05-18 BTIG Downgrades Outlook Therapeutics to Neutral From Buy MT
01-05 Chardan Adjusts Price Target on Outlook Therapeutics to $1 From $3, Maintains Neutral Rating MT
25-09-29 Outlook Therapeutics Plans to Resubmit ONS-5010 Biologics License Application Before Year-End MT
25-09-29 Outlook Therapeutics provides update on Type A Meeting with FDA RE
25-08-29 Outlook Therapeutics Shares Fall After HC Wainwright Downgrade MT
25-08-29 HC Wainwright Downgrades Outlook Therapeutics to Neutral From Buy, Adjusts Price Target to $1 From $3 MT
25-08-28 Guggenheim Downgrades Outlook Therapeutics to Neutral From Buy MT
24-12-02 Chardan Downgrades Outlook Therapeutics to Neutral From Buy, Puts Price Target 'Under Review' After $53 Price Target MT
24-03-27 BTIG Upgrades Outlook Therapeutics to Buy From Neutral, Price Target at $50 MT
24-02-15 Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target; Says Risk/Reward is Favorable for Lytenava BLA Resubmission MT
24-02-15 Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target MT
24-01-25 Guggenheim Upgrades Outlook Therapeutics to Buy From Neutral, Sets Price Target at $2 MT
24-01-25 Brookline Capital Upgrades Outlook Therapeutics to Buy From Hold, Price Target is $1.57 MT
23-12-27 Capital One Upgrades Outlook Therapeutics to Overweight From Equalweight With $5 Price Target MT
23-08-31 Chardan Downgrades Outlook Therapeutics to Neutral From Buy MT
23-08-31 HC Wainwright Downgrades Outlook Therapeutics to Neutral From Buy, Price Target is $1 MT
23-08-30 Brookline Capital Downgrades Outlook Therapeutics to Hold From Buy MT
23-08-30 Cantor Fitzgerald Downgrades Outlook Therapeutics to Neutral From Overweight, Adjusts Price Target to $1 From $4.50 MT
23-08-30 BTIG Downgrades Outlook Therapeutics to Neutral From Buy MT
23-07-13 Capital One Initiates Outlook Therapeutics With Overweight Rating, $5 Price Target MT
23-04-03 Guggenheim Initiates Outlook Therapeutics at Buy With $5 Price Target MT
23-02-06 Cantor Fitzgerald Initiates Outlook Therapeutics at Overweight With $4 Price Target MT
23-01-06 HC Wainwright Adjusts Price Target on Outlook Therapeutics to $5 From $6, Maintains Buy Rating MT
22-10-31 BTIG Starts Outlook Therapeutics at Buy With $7 Price Target MT
22-09-13 Chardan Capital Starts Outlook Therapeutics at Buy With $10 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+248.1%
+33.05%
+14.91%
+52.64%
+34.39%
+49.16%
-3.63%
+13.38%
+41.54%
Average +53.73%
Weighted average by Cap. +32.08%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.580USD
Average target price
5.500USD
Spread / Average Target
+248.10%
High Price Target
10.00USD
Spread / Highest target
+532.91%
Low Price Target
0.5000USD
Spread / Lowest Target
-68.35%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BTIG
Chardan Research
HC Wainwright
Guggenheim
Brookline Capital Markets
Capital One Securities
Cantor Fitzgerald
Ascendiant Capital
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.580USD
Average target price
5.500USD
Spread / Average Target
+248.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock
  4. Consensus Outlook Therapeutics, Inc.
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!